Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study

Laquinimod is a novel orally administered drug for the treatment of relapsing remitting multiple sclerosis (RRMS). In this immunological substudy of the phase III Assessment of Oral Laquinimod in Preventing Progression of MS (ALLEGRO) trial, we performed an ex vivo and in vitro analysis of effects e...

Descripción completa

Detalles Bibliográficos
Autores principales: Stasiolek, Mariusz, Linker, Ralf A, Hayardeny, Liat, Bar Ilan, Oren, Gold, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444148/
https://www.ncbi.nlm.nih.gov/pubmed/26029365
http://dx.doi.org/10.1002/iid3.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444148/
https://www.ncbi.nlm.nih.gov/pubmed/26029365
http://dx.doi.org/10.1002/iid3.42

Ejemplares similares